Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.79 |
| ▸ | CDK4 | P11802 | 8/20 | 0.79 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.79 |
| ▸ | CDK1 | P06493 | 2/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684643 | 0.89 | CDK2 (0.86) | CDK2CDK4CCNE1CDK1MAPT | |
| SCHEMBL1684810 | 0.89 | CDK2 (0.74) | CDK2CDK4CCNE1CDK1MAPT | |
| SCHEMBL1684719 | 0.89 | CDK2 (0.74) | CDK2CDK4CCNE1CDK1AURKB | |
| SCHEMBL1684709 | 0.87 | CDK2 (0.83) | CDK2CDK4CCNE1CDK1MAPT | |
| SCHEMBL1684885 | 0.87 | CDK2 (0.83) | CDK2CDK4CCNE1CDK1MAPT | |
| SCHEMBL1684889 | 0.87 | CDK2 (1.00) | CDK2CDK4CCNE1CDK1MAPT | |
| SCHEMBL1684609 | 0.85 | MAPT (0.67) | CDK2CDK4CCNE1CDK1AURKA | |
| SCHEMBL1684908 | 0.85 | CDK2 (0.79) | CDK2CDK4CCNE1CDK1AURKB | |
| SCHEMBL1684670 | 0.83 | CDK2 (0.76) | CDK2CDK4CCNE1CDK1AURKB | |
| SCHEMBL1684693 | 0.83 | CDK2 (0.80) | CDK2CDK4CCNE1CDK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | claimed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| EP-2306836-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010002985-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3111956-A1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | BMI1, CREBBP, BAZ2A | CDK2 1442/4885CDK4 1500/4885CCNE1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.